Chronic immune response dysregulation in MDS pathogenesis

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

Pyroptosis: host cell death and inflammation

Bergsbaken, T., Fink, S. L., & Cookson, B. T. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2070 · Cited by 3,288

Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease

Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683

Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer

WISEMAN, H., & HALLIWELL, B. (1996) · Biochemical Journal · doi:10.1042/bj3130017 · Cited by 2,345

Recurring mutations found by sequencing an acute myeloid leukemia genome

Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219

Long-Term Lymphohematopoietic Reconstitution by a Single CD34-Low/Negative Hematopoietic Stem Cell

Osawa, M., Hanada, K., Hamada, H., & Nakauchi, H. (1996) · Science · doi:10.1126/science.273.5272.242 · Cited by 2,141

The origin and evolution of mutations in acute myeloid leukemia

Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575

Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice

Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536

BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis

Kaufmann, E., Sanz, J., Dunn, J. L., Khan, N., Mendonça, L. E., Pacis, A., Tzelepis, F., Pernet, E., Dumaine, A., Grenier, J.-C., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.031 · Cited by 1,191

Dnmt3a is essential for hematopoietic stem cell differentiation

Challen, G. A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J. S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., et al. (2012) · Nature Genetics · doi:10.1038/ng.1009 · Cited by 1,122

Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling

Hormaechea-Agulla, D., Matatall, K. A., Le, D. T., Kain, B., Long, X., Kus, P., Jaksik, R., Challen, G. A., Kimmel, M., & King, K. Y. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.03.002 · Cited by 329

Inflammation-Induced Tumorigenesis and Metastasis

Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata‐Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 319

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Sallman, D. A., & List, A. (2019) · Blood · doi:10.1182/blood-2018-10-844654 · Cited by 273

U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies

Smith, M. A., Choudhary, G. S., Pellagatti, A., Choi, K., Bolanos, L. C., Bhagat, T. D., Gordon-Mitchell, S., Ahrens, D. V., Pradhan, K., Steeples, V., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0314-5 · Cited by 253

Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS

Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189

Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs

Muto, T., Walker, C. S., Choi, K., Hueneman, K., Smith, M. A., Gul, Z., Garcia-Manero, G., Ma, A., Zheng, Y., & Starczynowski, D. T. (2020) · Nature Immunology · doi:10.1038/s41590-020-0663-z · Cited by 155

An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia

Lasry, A., Nadorp, B., Fornerod, M. W. J., Nicolet, D., Wu, H., Walker, C. J., Sun, Z., Witkowski, M. T., Tikhonova, A. N., Guillamot, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00480-0 · Cited by 157

Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1

Zhang, J., Ali, A. M., Lieu, Y. K., Liu, Z., Gao, J., Rabadán, R., Raza, A., Mukherjee, S., & Manley, J. L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.017 · Cited by 127

IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies

Bennett, J., & Starczynowski, D. T. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000693 · Cited by 100

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia

Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 103

Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia

Chlon, T. M., Stepanchick, E., Hershberger, C. E., Daniels, N. J., Hueneman, K. M., Davis, A. K., Choi, K., Zheng, Y., Gurnari, C., Haferlach, T., et al. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.08.004 · Cited by 94

PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress

Chavez, J. S., Rabe, J. L., Loeffler, D., Higa, K. C., Hernandez, G., Mills, T. S., Ahmed, N., Gessner, R. L., Ke, Z., Idler, B. M., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201169 · Cited by 91

Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells

Carenza, C., Calcaterra, F., Oriolo, F., Vito, C. D., Ubezio, M., Porta, M. G. D., Mavilio, D., & Bella, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01325 · Cited by 91

Myelodysplastic syndromes

Li, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 96

Clonal hematopoiesis and inflammation – the perpetual cycle

Avagyan, S., & Zon, L. I. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.12.001 · Cited by 79

Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets

Wang, T., Pine, A. R., Kotini, A. G., Yuan, H., Zamparo, L., Starczynowski, D. T., Leslie, C. S., & Papapetrou, E. P. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.011 · Cited by 77

Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations

Choudhary, G. S., Pellagatti, A., Agianian, B., Smith, M. A., Bhagat, T. D., Gordon-Mitchell, S., Sahu, S., Pandey, S., Shah, N. N., Aluri, S., et al. (2022) · eLife · doi:10.7554/elife.78136 · Cited by 76

Environmental influences on clonal hematopoiesis

King, K. Y., Huang, Y., Nakada, D., & Goodell, M. A. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.005 · Cited by 75

The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MYD88 degradation

Guillamot, M., Ouazia, D., Dolgalev, I., Yeung, S. T., Kourtis, N., Dai, Y., Corrigan, K., Zea-Redondo, L., Saraf, A., Florens, L. A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0454-6 · Cited by 70

Inflammatory Modulation of Hematopoiesis: Linking Trained Immunity and Clonal Hematopoiesis with Chronic Disorders

Chavakis, T., Wielockx, B., & Hajishengallis, G. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-052521-013627 · Cited by 75

Bone marrow–confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia

Mei, Y., Ren, K.-H., Liu, Y.-J., Ma, A., Xia, Z., Han, X., Li, E., Tariq, H., Bao, H., Xie, X., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152673 · Cited by 44

DDX41-associated susceptibility to myeloid neoplasms

Makishima, H., Bowman, T. V., & Godley, L. A. (2022) · Blood · doi:10.1182/blood.2022017715 · Cited by 61

TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity

Muto, T., Guillamot, M., Yeung, J., Fang, J., Bennett, J. R., Nadorp, B., Lasry, A., Zea-Redondo, L., Choi, K., Gong, Y., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2021.12.007 · Cited by 60

Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes

Hsu, J., Reilly, A., Hayes, B. J., Clough, C. A., Konnick, E. Q., Torok‐Storb, B., Gülsüner, S., Wu, D., Becker, P. S., Keel, S., et al. (2019) · Blood · doi:10.1182/blood.2018884338 · Cited by 63

Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies

Camacho, V., Kuznetsova, V., & Welner, R. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772408 · Cited by 60

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML

Bennett, J. R., Ishikawa, C., Agarwal, P., Yeung, J., Sampson, A. M., Uible, E. E., Vick, E. J., Bolanos, L. C., Hueneman, K. M., Wunderlich, M., et al. (2023) · Blood · doi:10.1182/blood.2022018718 · Cited by 58

Bone marrow inflammation in haematological malignancies

de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54

Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?

Hochman, M. J., & Dezern, A. E. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00138-7 · Cited by 53

Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome

Ribezzo, F., Snoeren, I. A. M., Ziegler, S., Stoelben, J., Olofsen, P. A., Henic, A., Ferreira, M. V., Chen, S., Stalmann, U. S. A., Buesche, G., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0350-3 · Cited by 51

Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes

Banerjee, T., Calvi, L. M., Becker, M. W., & Liesveld, J. L. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.004 · Cited by 53

Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes

Paracatu, L. C., & Schuettpelz, L. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01236 · Cited by 51

Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia

Weeks, L. D., Marinac, C. R., Redd, R. A., Abel, G. A., Lin, A. E., Agrawal, M., Stone, R. M., Schrag, D., & Ebert, B. L. (2021) · Blood · doi:10.1182/blood.2021014418 · Cited by 48

Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies

Saygin, C., Roloff, G. W., Hahn, C. N., Chhetri, R., Gill, S. I., Elmariah, H., Talati, C., Nunley, E., Gao, G., Kim, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008172 · Cited by 48

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes

Kouroukli, O., Symeonidis, A. S., Foukas, P. G., Maragkou, M., & Kourea, E. P. (2022) · Cancers · doi:10.3390/cancers14225656 · Cited by 52

Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia

Barreyro, L., Sampson, A. M., Ishikawa, C., Hueneman, K. M., Choi, K., Pujato, M. A., Chutipongtanate, S., Wyder, M. A., Haffey, W. D., O'Brien, E. J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abb7695 · Cited by 45

The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms

Balandrán, J. C., Lasry, A., & Aifantis, I. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0176 · Cited by 44

H2S exposure induces cell death in the broiler thymus via the ROS-initiated JNK/MST1/FOXO1 pathway

Chi, Q., Hu, X., Liu, Z., Han, Y., Tao, D., Xu, S., & Li, S. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112488 · Cited by 39

Iron overload and its impact on outcome of patients with hematological diseases

Franke, G., Kubasch, A. S., Cross, M. A., Vučinić, V., & Platzbecker, U. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100868 · Cited by 40

Therapeutic targeting of the inflammasome in myeloid malignancies

Chakraborty, S., Shapiro, L. C., de Oliveira, S., Rivera-Peña, B., Verma, A. K., & Shastri, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00547-8 · Cited by 40

Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges

Tsilingiris, D., Vallianou, N. G., Spyrou, N., Kounatidis, D. C., Christodoulatos, G. S., Karampela, Ι., & Dalamaga, Μ. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00542-z · Cited by 42

T-cell dysfunctions in myelodysplastic syndromes

Rodríguez‐Sevilla, J. J., & Colla, S. (2024) · Blood · doi:10.1182/blood.2023023166 · Cited by 37

Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer

Feng, Y., Chen, C., Shao, A., Wu, L., Hu, H., & Zhang, T. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.008 · Cited by 40

TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis

Niederkorn, M., Hueneman, K. M., Choi, K., Varney, M., Romano, L. M., Pujato, M., Greis, K., Inoue, J., Meetei, R. A., & Starczynowski, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.093 · Cited by 36

Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes

van Leeuwen-Kerkhoff, N., Westers, T. M., Poddighe, P. J., Povoleri, G. A. M., Timms, J. A., Kordasti, S. Y., de Gruijl, T. D., & van de Loosdrecht, A. A. (2021) · Haematologica · doi:10.3324/haematol.2020.268136 · Cited by 37

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

Lee, P., Yim, R., Yung, Y., Chu, H.-T., Yip, P.-K., & Gill, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910232 · Cited by 40

Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes

Aoyagi, Y., Hayashi, Y., Harada, Y., Choi, K., Matsunuma, N., Sadato, D., Maemoto, Y., Ito, A., Yanagi, S., Starczynowski, D. T., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0032 · Cited by 35

Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune‑mediated bone marrow failure syndromes (Review)

Votavová, H., & Beličková, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5297 · Cited by 37

Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia

Naji, N. S., Sathish, M., & Karantanos, T. (2024) · Cancers · doi:10.3390/cancers16233974 · Cited by 38

Immuno-Modulation of Hematopoietic Stem and Progenitor Cells in Inflammation

Sezaki, M., Hayashi, Y., Wang, Y., Johansson, A., Umemoto, T., & Takizawa, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585367 · Cited by 38

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes

Wang, Y., Hou, H., Lin, C., Kuo, Y., Yao, C., Hsu, C., Tseng, M., Tsai, C., Peng, Y., Kao, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005141 · Cited by 37

Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients

Silzle, T., Blum, S., Schuler, E., Kaivers, J., Rudelius, M., Hildebrandt, B., Gattermann, N., Haas, R. R., & Germing, U. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0223-7 · Cited by 33

Activation of distinct inflammatory pathways in subgroups of LR-MDS

Schneider, M., Rolfs, C., Trumpp, M., Winter, S., Fischer, L., Richter, M., Menger, V., Nenoff, K., Grieb, N., Metzeler, K. H., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01949-2 · Cited by 32

FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome

Schieber, M., Marinaccio, C., Bolanos, L. C., Haffey, W. D., Greis, K. D., Starczynowski, D. T., & Crispino, J. D. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00362-7 · Cited by 28

TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease

Niederkorn, M., Agarwal, P., & Starczynowski, D. T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.08.010 · Cited by 31

Real‐world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts

Farrukh, F., Chetram, D. K., Al‐Kali, A., Foran, J. M., Patnaik, M. M., Badar, T., Begna, K. H., Hook, C. C., Hogan, W. J., McCullough, K. B., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26533 · Cited by 28

Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective

Hayashi, Y., Harada, Y., & Harada, H. (2022) · Leukemia · doi:10.1038/s41375-022-01548-7 · Cited by 27

Autoimmune disease in CMML-the chicken or the egg?

Ambinder, A. J., Miller, J. B., & Dezern, A. E. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.101136 · Cited by 28

CCR5 maintains macrophages in the bone marrow and drives hematopoietic failure in a mouse model of severe aplastic anemia

Seyfried, A. N., McCabe, A. F., Smith, J. N. P., Calvi, L. M., & MacNamara, K. C. (2021) · Leukemia · doi:10.1038/s41375-021-01219-z · Cited by 25

Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review

Lynch, O. F., & Calvi, L. M. (2022) · Cells · doi:10.3390/cells11030580 · Cited by 27

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

Taylor, J., Mi, X., Penson, A. V., Paffenholz, S. V., Alvarez, K., Sigler, A. M., Chung, S. S., Rampal, R. K., Park, J. H., Stein, E. M., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30209-x · Cited by 24

Malignant Transformation Involving CXXC4 Mutations Identified in a Leukemic Progression Model of Severe Congenital Neutropenia

Olofsen, P. A., Fátrai, S., van Strien, P. M. H., Obenauer, J. C., de Looper, H. W. J., Hoogenboezem, R. M., Erpelinck-Verschueren, C. A. J., Vermeulen, M., Roovers, O., Haferlach, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100074 · Cited by 24

Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis

Herrera, D. A., Sparks, A. D., Singh, R., Alejos, D., Batra, A., Glushakow-Smith, S. G., Pradhan, K., Shastri, A., & Zakai, N. A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011050 · Cited by 22

Clonal hematopoiesis in adult pure red cell aplasia

Fujishima, N., Kohmaru, J., Koyota, S., Kuba, K., Saga, T., Omokawa, A., Moritoki, Y., Ueki, S., Ishida, F., Nakao, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-81890-5 · Cited by 21

Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Barakos, G. P., & Hatzimichael, E. C. (2022) · Diseases · doi:10.3390/diseases10020033 · Cited by 24

Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation

Rodríguez‐Sevilla, J. J., Ademà, V., Garcia‐Manero, G., & Colla, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100940 · Cited by 23

TNFAIP3 Plays a Role in Aging of the Hematopoietic System

Smith, M. A., Culver‐Cochran, A. E., Adelman, E. R., Rhyasen, G. W., Ma, A. I., Figueroa, M. E., & Starczynowski, D. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.536442 · Cited by 20

The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options

Costanzo, A. D., Gaudio, N. D., Conte, L., & Altucci, L. (2020) · Cancers · doi:10.3390/cancers12071898 · Cited by 22

Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis

Varricchio, L., & Hoffman, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906698 · Cited by 21

Plasmacytoid Dendritic Cells, a Novel Target in Myeloid Neoplasms

Roussel, X., Garnache‐Ottou, F., & Renosi, F. (2022) · Cancers · doi:10.3390/cancers14143545 · Cited by 21

MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells

Pollyea, D. A., Kim, H. M., Stevens, B. M., Lee, F. F.-Y., Harris, C., Hedin, B. R., Knapp, J. R., O’Connor, B. P., Jordan, C. T., Pietras, E. M., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.6ab0520-318rr · Cited by 20

TIRAP drives myelosuppression through an Ifnγ–Hmgb1 axis that disrupts the endothelial niche in mice

Gopal, A., Ibrahim, R., Fuller, M., Umlandt, P., Parker, J., Tran, J., Chang, L., Wegrzyn-Woltosz, J., Lam, J., Li, J., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200731 · Cited by 20

Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS

Velegraki, M., Stiff, A. R., Papadaki, H. Α., & Li, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164908 · Cited by 20

Joint representation and visualization of derailed cell states with Decipher

Nazaret, A., Fan, J. L., Lavallée, V., Burdziak, C., Cornish, A. E., Kiseliovas, V., Bowman, R. L., Masilionis, I., Chun, J., Eisman, S. E., et al. (2025) · Genome biology · doi:10.1186/s13059-025-03682-8 · Cited by 16

Targeting inflammation in lower-risk MDS

Gonzalez‐Lugo, J. D., & Verma, A. K. (2022) · Hematology · doi:10.1182/hematology.2022000350 · Cited by 19

Role of IL8 in myeloid malignancies

Ramachandra, N., Gupta, M., Schwartz, L. Y., Todorova, T. I., Shastri, A., Will, B., Steidl, U. G., & Verma, A. K. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2232492 · Cited by 19

Immune dysregulation and potential targeted therapy in myelodysplastic syndrome

Zhang, X., Yang, X., Ma, L., Zhang, Y., & Wei, J. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231183330 · Cited by 19

Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation

Stoner, S. A., Yan, M., Liu, K. T. H., Arimoto, K., Shima, T., Wang, H., Johnson, D. T., Bejar, R. L., Jamieson, C. H. M., Guan, K., et al. (2019) · Blood · doi:10.1182/blood.2019000170 · Cited by 19

The role of inflammations and EMT in carcinogenesis

Islam, M. S., Morshed, M. R., Babu, G., & Khan, M. A. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100055 · Cited by 18

Impact of transfusion on survival in patients with myelodysplastic syndromes: Current knowledge, new insights and transfusion clinical practice

Kaphan, É., Laurin, D., Lafeuillade, B., Drillat, P., & Park, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100649 · Cited by 17

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Reville, P. K., Wang, B., Marvin‐Peek, J., Yuan, B., Kuo, Y.-J., Garza, A. I., Root, J. L., Qiao, W., Arruda, A., Veletić, I., et al. (2025) · Blood · doi:10.1182/blood.2024027244 · Cited by 17

Preleukemic and leukemic evolution at the stem cell level

Stauber, J., Greally, J. M., & Steidl, U. G. (2020) · Blood · doi:10.1182/blood.2019004397 · Cited by 20

Single-cell genomics in acquired bone marrow failure syndromes

Wu, Z., & Young, N. S. (2023) · Blood · doi:10.1182/blood.2022018581 · Cited by 19

Truncated CSF3 receptors induce pro‐inflammatory responses in severe congenital neutropenia

Olofsen, P. A., Bosch, D. A., de Looper, H. W. J., van Strien, P. M. H., Hoogenboezem, R. M., Roovers, O., van der Velden, V. H. J., Bindels, E. M., de Pater, E., & Touw, I. P. (2022) · British Journal of Haematology · doi:10.1111/bjh.18477 · Cited by 16

Inflammatory profile of lower risk myelodysplastic syndromes

Topping, J., Taylor, A., Nadat, F., Crouch, S., Ibbotson, A., Čermák, J., Symeonidis, A. S., Tatic, A., Langemeijer, S. M. C., Hellström‐Lindberg, E., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19530 · Cited by 16

The rewired immune microenvironment in leukemia

Ciantra, Z. B., Paraskevopoulou, V., & Aifantis, I. (2025) · Nature Immunology · doi:10.1038/s41590-025-02096-9 · Cited by 19

Genetic and environmental risks for clonal hematopoiesis and cancer

Franco, S., & Godley, L. A. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230931 · Cited by 15

Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal

Xu, J. J., Smeets, M. F. M. A., Tan, S. Y., Wall, M., Purton, L. E., & Walkley, C. R. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.11.001 · Cited by 15

Inflammasome Activation in Myeloid Malignancies—Friend or Foe?

Andina, N. D., Bonadies, N., & Allam, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.825611 · Cited by 15

A neural network-based method for exhaustive cell label assignment using single cell RNA-seq data

Li, Z., & Feng, H. (2022) · Scientific Reports · doi:10.1038/s41598-021-04473-4 · Cited by 14

PU.1 is required to restrain myelopoiesis during chronic inflammatory stress

Chavez, J. S., Rabe, J. L., Niño, K. E., Wells, H. H., Gessner, R. L., Mills, T. S., Hernandez, G., & Pietras, E. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1204160 · Cited by 14

High BM plasma S100A8/A9 is associated with a perturbed microenvironment and poor prognosis in myelodysplastic syndromes

Wang, Y., Lin, C., Yao, C., Amaral, F. M. R., Yu, S., Kao, C., Shih, P., Hou, H., Chou, W., & Tien, H. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008958 · Cited by 14

Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes

Vallelonga, V., Gandolfi, F., Ficara, F., Porta, M. G. D., & Ghisletti, S. (2023) · Biomedicines · doi:10.3390/biomedicines11102613 · Cited by 15

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML

Barreyro, L., Sampson, A. M., Hueneman, K. M., Choi, K., Christie, S., Ramesh, V., Wyder, M. A., Wang, D., Pujato, M. A., Greis, K. D., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109809 · Cited by 14

Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia

Sunthankar, K. I., Jenkins, M. T., Cote, C. H., Patel, S. B., Welner, R. S., & Ferrell, P. B. (2021) · Leukemia · doi:10.1038/s41375-021-01487-9 · Cited by 12

Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion

Stalmann, U., Ticconi, F., Snoeren, I., Li, R., Gleitz, H. F. E., Cowley, G. S., McConkey, M. E., Wong, A. B., Schmitz, S., Fuchs, S. N. R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006061 · Cited by 11

Inhibitor of DNA binding proteins revealed as orchestrators of steady state, stress and malignant hematopoiesis

Singh, S., Sarkar, T., Jakubison, B. L., Gadomski, S. J., Spradlin, A., Gudmundsson, K. O., & Keller, J. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.934624 · Cited by 12

ERVs-TLR3-IRF axis is linked to myelodysplastic syndrome pathogenesis

de Oliveira, R. T. G., Cordeiro, J. V. A., Vitoriano, B. F., Melo, M. M. D. L., Sampaio, L. R., Borges, D. D. P., Magalhães, S. M. M., & Pinheiro, R. F. (2021) · Medical Oncology · doi:10.1007/s12032-021-01466-1 · Cited by 12

MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes

Giallongo, C., Dulcamare, I., Giallongo, S., Duminuco, A., Pieragostino, D., Cufaro, M. C., Amorini, A. M., Lazzarino, G., Romano, A., Parrinello, N. L., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06197-x · Cited by 12

DDX41 haploinsufficiency causes inefficient hematopoiesis under stress and cooperates with p53 mutations to cause hematologic malignancy

Stepanchick, E., Wilson, A., Sulentic, A., Choi, K., Hueneman, K. M., Starczynowski, D. T., & Chlon, T. M. (2024) · Leukemia · doi:10.1038/s41375-024-02304-9 · Cited by 11

Cancer-associated SF3B1-K700E mutation controls immune responses by regulating T reg function via aberrant Anapc13 splicing

Shi, Y., Zhang, W., Jia, Q., Zhong, X., Iyer, P. S., Wu, H., Yuan, Y., Zhao, Y., Zhang, L., Wang, L., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado4274 · Cited by 11

Chronic Innate Immune Signaling in Myelodysplasia

Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-99-109492

Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

Gañán-Gómez, I., Wei, Y., Starczynowski, D. T., Colla, S., Yang, H., Cabrero-Calvo, M., Bohannan, Z. S., Verma, A., Steidl, U., & Garcia-Manero, G. (2015) · Leukemia · doi:10.1038/leu.2015.69 · Cited by 236

Deconstructing innate immune signaling in myelodysplastic syndromes

Varney, M. E., Melgar, K., Niederkorn, M., Smith, M. A., Barreyro, L., & Starczynowski, D. T. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.016 · Cited by 38

Innate Immune Signaling in the Myelodysplastic Syndromes

Starczynowski, D. T., & Karsan, A. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.008 · Cited by 47

Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review

Vegivinti, C. T. R., Keesari, P. R., Veeraballi, S., Maia, C., Mehta, A. K., Lavu, R. R., Thakur, R., Tella, S. H., Patel, R. J., Kakumani, V. K., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00422-1 · Cited by 43